FRZB and renal carcinoma: The present investigation demonstrates that vessel dilator, KP, ANP and LANP decreased the levels of sFRP-3 by 77–78% in human pancreatic cancer cells, 83–84% in human colorectal cancer cells and 66–68% in human renal cancer cells.